STOCK TITAN
  1. Home
  2. Sec-filings
  3. ONC
  4. [Form 4] BeOne Medicines Ltd. American Insider Trading Activity

ONC Insider Filing Shows 0.3% Stake Trim by Xiaodong Wang

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

BeOne Medicines (ONC) filed a routine Form 4 disclosing that Director and Scientific Advisory Board Chair Xiaodong Wang sold an aggregate 2,007 American Depositary Shares (each equal to 13 ordinary shares) on 06/24/2025 under a Rule 10b5-1 plan at prices ranging from $263.40 – $267.81. The total consideration is roughly $0.53 million, representing about 0.3 % of his total beneficial ownership. No new grants, derivative transactions, or governance changes were reported.

Positive

  • None.

Negative

  • None.
Insider Wang Xiaodong
Role Director
Sold 2,007 shs ($533K)
Type Security Shares Price Value
Sale American Depositary Shares 300 $263.50 $79K
Sale American Depositary Shares 1,100 $265.3525 $292K
Sale American Depositary Shares 507 $266.5653 $135K
Sale American Depositary Shares 100 $267.81 $27K
holding Ordinary Shares -- -- --
holding Ordinary Shares -- -- --
holding Ordinary Shares -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: American Depositary Shares — 1,707 shares (Direct); Ordinary Shares — 5,154,770 shares (Direct); Ordinary Shares — 1,025,063 shares (Indirect, See Footnote)
Footnotes (1)
  1. These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership. These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership. These securities are held by the spouse of the Reporting Person. Each American Depositary Share represents 13 Ordinary Shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.40 to $263.55, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.02 to $265.86, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.27 to $266.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wang Xiaodong
(Last) (First) (Middle)
C/O BEONE MEDICINES I GMBH
AESCHENGRABEN 27, 21ST FLOOR
(Street)
BASEL V8 4051
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) X Other (specify below)
Chair, Scientific Advisory Brd
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 5,154,770 D
Ordinary Shares 1,025,063 I See Footnote(1)
Ordinary Shares 3,953,100 I See Footnote(2)
Ordinary Shares 50 I See Footnote(3)
American Depositary Shares(4) 06/24/2025 S(5) 300 D $263.5(6) 1,707 D
American Depositary Shares(4) 06/24/2025 S(5) 1,100 D $265.3525(7) 607 D
American Depositary Shares(4) 06/24/2025 S(5) 507 D $266.5653(8) 100 D
American Depositary Shares(4) 06/24/2025 S(5) 100 D $267.81 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.
2. These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.
3. These securities are held by the spouse of the Reporting Person.
4. Each American Depositary Share represents 13 Ordinary Shares.
5. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.40 to $263.55, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.02 to $265.86, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.27 to $266.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Remarks:
/s/ Qing Nian, as Attorney-in-Fact 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many shares did ONC Director Xiaodong Wang sell in the June 2025 Form 4?

He sold 2,007 American Depositary Shares, equivalent to about 26,091 ordinary shares.

What was the total value of the ONC insider sale reported on 06/24/2025?

The transactions were valued at approximately $0.53 million based on weighted average prices of $263.40–$267.81 per ADS.

Did the June 2025 Form 4 significantly change Xiaodong Wang's ownership in ONC?

No. The sale reduced his direct ADS holdings to zero but cut overall ownership by only ≈0.3 %.

Was the insider sale executed under a Rule 10b5-1 trading plan?

Yes. The filing states the sales were made pursuant to a 10b5-1 plan adopted on August 12, 2024.